Search:

Login | Subscribe

Home > Companies > Immupharma

Price	Market	Sector	Market Cap
45.00p (-1.50p) -3.23%	AIM	Medicine and Biotech Research	£34.81m

Add to company folder | Print

Related Companies

AGY	10.25p	-19.61%
APH	4.62p	0.00%
AZH	p
BBI	p
CEN	p
CBF	3.00p	-7.69%
COT	101.50p	-9.78%
CRX	2.12p	0.00%
CYX	p
LAC	p
EVC	26.25p	-3.67%
FUL	2.75p	-8.33%
FUM	25.25p	-17.89%
GMX	2.50p	0.00%
GNI	p
GWP	26.50p	-30.72%
HML	0.42p	-5.56%
MLR	p
MMG	7.00p	-5.08%
MPM	15.50p	-7.46%

Commentary

Specialist pharmaceutical discovery and development

Recent Articles

ImmuPharma ponders funding	01/07/2008
ImmuPharma hails cancer progress	20/05/2008
Directors’ dealings by Andrew Hore	07/02/2008
A more palatable pill	05/10/2007
Turning point for shells	10/07/2006
Phase II for ImmuPharma	06/07/2006
Internet Music & Media	01/07/2002
Internet Music & Media	28/09/2001
Looking ahead	01/12/2000
Internet Music & Media	01/11/2000
More

Recent Announcements

Interim Results	25/09/2008
AGM Result	05/08/2008
Second Placing	10/07/2008
Toxicology study	02/07/2008
Fund Raising	02/07/2008
Annual Report and Accounts	30/06/2008
Pre-clinical Data	20/05/2008
Trademark Approval	13/05/2008
Preliminary Results	08/05/2008
Phase IIb Trial of IPP-201101	26/02/2008
More

Articles from the Sector

Sinclair Pharma	03/10/2008
Forex boost for Sinclair Pharma	01/10/2008
US approves ProStrakan patch	15/09/2008
RCG Holdings	02/09/2008
Source BioScience plans restructure	28/08/2008
Asterand slashes interim loss	27/08/2008
ProStrakan targets USA	21/08/2008
Proximagen	18/08/2008
Chi-Med bullish despite interim losses	06/08/2008
Pharmaceuticals & biotechnology	04/08/2008
More

Financial History

Financial Year End	28/02/2003	31/12/2003	31/03/2004	31/12/2006	31/12/2007
Currency	GBP	GBP	GBP	GBP	GBP
Turnover	0.00	0.00	0.00	0.04	0.06
Operating Profit	0.00	-0.14	-0.01	-1.97	-3.53
Pretax Profit	0.00	-3.22	0.00	-1.91	-3.34
Earnings After Tax	0.00	-3.22	0.00	-1.86	-3.08
Profit Available For Dividend	0.00	0.00	0.00	0.00	0.00
Ordinary Dividends	0.00	0.00	0.00	0.00	0.00
Retained Profit	0.00	-3.22	0.00	0.00	0.00
Shareholders Funds	0.00	-2.20	0.98	5.89	3.05
Net Current Assets	0.00	-2.20	0.98	0.00	0.00
Adjusted Earnings Per Share Undiluted	0.00	0.00	0.00	-3.61	-4.24
Adj Earnings Per Share	0.00	0.00	0.00	-3.61	-4.24
Dividend Per Share	0.00	0.00	0.00	0.00	0.00

Chart

Click here for interactive charting

Company Details
Address	50 Broadway, Westminster, London, SW1H 0RG
Telephone	020 7152 4080
Fax	020 7152 4001
Executives
Chairman	Richard Warr (16.30% holding)
Chief Executive	Dimitri Dimitriou (16.30% holding)
Finance Director	Paddy Walker-Taylor (0.00% holding)
Chief Scientific Officer	Robert Zimmer (33.80% holding)
Main Shareholders
	Modulus Europe: 5.2%
Advisers
Nominated Adviser	Panmure Gordon
Nominated Broker	Panmure Gordon
Solicitors	Bircham Dyson Bell
Auditors	Nexia Smith & Williamson
Registrar	Computershare Investor Services

Commentary
Specialist pharmaceutical discovery and development
Company Data
Code	IMM
Sedol	GB00337110
Shares In Issue	77.349 m
Indices
Entry on AIM	28/10/2003
Interim Results	Sep
Final Results	May
Year End	Dec
Accounts Due	Jun
Int div payment	n/a
Fin div payment	n/a
Int net div per share	nil
Fin net div per share	nil
Probable CGT relief	Yes